Advisor Partners’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $3.65M | Buy |
65,532
+3,722
| +6% | +$207K | 0.26% | 70 |
|
|
2022
Q1 | $3.43M | Sell |
61,810
-3,846
| -6% | -$197K | 0.21% | 86 |
|
|
2021
Q4 | $3.68M | Buy |
65,656
+2,112
| +3% | +$114K | 0.22% | 83 |
|
|
2021
Q3 | $3.05M | Sell |
63,544
-1,460
| -2% | -$70.6K | 0.21% | 92 |
|
|
2021
Q2 | $2.72M | Buy |
65,004
+974
| +2% | +$37.8K | 0.18% | 107 |
|
|
2021
Q1 | $2.16M | Buy |
64,030
+6,296
| +11% | +$224K | 0.15% | 133 |
|
|
2020
Q4 | $2.02M | Buy |
57,734
+2,098
| +4% | +$72.5K | 0.15% | 137 |
|
|
2020
Q3 | $1.93M | Buy |
55,636
+1,858
| +3% | +$61.9K | 0.17% | 123 |
|
|
2020
Q2 | $1.76M | Buy |
53,778
+10,810
| +25% | +$345K | 0.16% | 128 |
|
|
2020
Q1 | $1.29M | Buy |
42,968
+9,348
| +28% | +$278K | 0.16% | 134 |
|
|
2019
Q4 | $1.05M | Buy |
33,620
+1,758
| +6% | +$48.7K | 0.11% | 185 |
|
|
2019
Q3 | $824K | Buy |
31,862
+2,290
| +8% | +$57.9K | 0.1% | 217 |
|
|
2019
Q2 | $755K | Buy |
29,572
+1,522
| +5% | +$37.6K | 0.09% | 222 |
|
|
2019
Q1 | $734K | Buy |
28,050
+2,782
| +11% | +$68.4K | 0.09% | 216 |
|
|
2018
Q4 | $582K | Buy |
25,268
+676
| +3% | +$15K | 0.09% | 235 |
|
|
2018
Q3 | $580K | Buy |
24,592
+3,822
| +18% | +$93.3K | 0.08% | 270 |
|
|
2018
Q2 | $479K | Sell |
20,770
-4,174
| -17% | -$99.2K | 0.08% | 289 |
|
|
2018
Q1 | $614K | Buy |
24,944
+3,744
| +18% | +$98.3K | 0.11% | 214 |
|
|
2017
Q4 | $613K | Buy |
21,200
+9,386
| +79% | +$239K | 0.11% | 218 |
|
|
2017
Q3 | $284K | Buy |
+11,814
| New | +$267K | 0.06% | 361 |
|
|
2017
Q1 | – | Sell |
-12,292
| Closed | -$220K | – | 445 |
|
|
2016
Q4 | $220K | Buy |
12,292
+2,074
| +20% | +$37.6K | 0.07% | 365 |
|
|
2016
Q3 | $212K | Buy |
+10,218
| New | +$253K | 0.07% | 350 |
|
|
2016
Q1 | – | Sell |
-15,668
| Closed | -$455K | – | 396 |
|
|
2015
Q4 | $455K | Buy |
15,668
+302
| +2% | +$8.36K | 0.16% | 156 |
|
|
2015
Q3 | $417K | Sell |
15,366
-896
| -6% | -$25.4K | 0.17% | 151 |
|
|
2015
Q2 | $444K | Buy |
16,262
+2,048
| +14% | +$57.6K | 0.17% | 168 |
|
|
2015
Q1 | $379K | Sell |
14,214
-1,674
| -11% | -$38.5K | 0.16% | 181 |
|
|
2014
Q4 | $354K | Buy |
15,888
+44
| +0.3% | +$983 | 0.16% | 177 |
|
|
2014
Q3 | $377K | Buy |
15,844
+2
| +0% | +$46 | 0.22% | 133 |
|
|
2014
Q2 | $366K | Sell |
15,842
-190
| -1% | -$4.2K | 0.18% | 161 |
|
|
2014
Q1 | $366K | Sell |
16,032
-318
| -2% | -$6.78K | 0.2% | 152 |
|
|
2013
Q4 | $302K | Buy |
16,350
+2,240
| +16% | +$39K | 0.17% | 172 |
|
|
2013
Q3 | $239K | Buy |
14,110
+660
| +5% | +$11.1K | 0.17% | 182 |
|
|
2013
Q2 | $208K | Buy |
+13,450
| New | +$224K | 0.17% | 186 |
|
Other funds holding NVO
F
Advisor Partners's NVO Position: Q2 2022 in Review
Advisor Partners increased its Novo Nordisk (NVO) stake by 6% in Q2 2022, buying an estimated $207K and bringing the position to 65,532 shares worth $3.65M. The position accounts for 0.26% of the portfolio, ranked #70.
Advisor Partners first reported a position in NVO in Q2 2013 and has held it in 33 quarters since. The position peaked at $3.68M in Q4 2021. 932 funds tracked by Wall St. Rank hold NVO as of Q2 2022.
- Advisor Partners held 65,532 shares of Novo Nordisk worth $3.65M as of Q2 2022.
- Advisor Partners bought 3,722 Novo Nordisk shares in Q2 2022, an estimated $207K.
- Novo Nordisk made up 0.26% of Advisor Partners's portfolio in Q2 2022, its #70 holding.
- Advisor Partners first reported a position in Novo Nordisk in Q2 2013 and has held it in 33 quarters since.
- Advisor Partners's Novo Nordisk position peaked at $3.68M in Q4 2021.
- 932 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.
Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.